Xie L, Xu J, Sun X, et al. Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial. J Immunother Cancer 2020;8:e000798. doi: 10.1136/jitc-2020-000798.
Since the online publication of this article, the authors have noticed that in figure 4 the dotted and full lines were mislabelled. Please see the corrected Figure below: